PRESS RELEASES

Date Title and Summary View
Toggle Summary PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE FROM 10X FUND View HTML
Toggle Summary COLOMBIAN PRESIDENT URIBE WELCOMES PRO-PHARMACEUTICALS AND INTRODUCTION OF DAVANAT® TO COLOMBIA View HTML
Toggle Summary PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2009 FINANCIAL RESULTS View HTML
Toggle Summary PRO-PHARMACEUTICALS CLOSES $335,000 TRANCHE View HTML
Toggle Summary PRO-PHARMACEUTICALS RECEIVES FINAL TRANCHE OF FUNDING FROM FEDERAL GRANT; RAISES CASH POSITION TO $8 MILLION View HTML
Toggle Summary PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE View HTML
Toggle Summary PRO-PHARMACEUTICALS ANNOUNCES SIGNIFICANT ADVANCE IN DEFINING DAVANAT®'s MECHANISM OF ACTION BASED ON EXPERIMENTS DONE AT THE UNIVERSITY OF MINNESOTA AND THE LUDWIG INSTITUTE IN BRUSSELS, BELGIUM
Studies Demonstrate DAVANAT® Binds To Galectin-1 and Galectin-3 Receptors That Control Angiogenesis and the Tumor's Ability To Evade the Immune System
View HTML
Toggle Summary THE LUDWIG INSTITUTE AND PRO-PHARMACEUTICALS COLLABORATE TO TEST DAVANAT®'s ABILITY TO ENHANCE THE FUNCTION OF ANTI-TUMOR T LYMPHOCYTES
Pro-Pharmaceuticals' DAVANAT® Targets Galectin Receptors on Cancer Cells and Removes Their Ability to Evade the Immune System
View HTML
Toggle Summary PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE View HTML
Toggle Summary Pro-Pharmaceuticals Reports Third Quarter Financial Results View HTML